The Global Pre-filled Syringe Market 2014-2024 report analyses how this important sub-sector will continue to grow across the next decade. The report highlights key companies, geographies and products that we believe will deliver double digit growth across the next decade. Buy this report today and acquire analysis of the state of the pre-filled syringes market in 2014 and a market forecastfor the period 2014-2024. Market forecasts are also provided for global pre-filled syringes for glass and plastics on the global level (value and volume) as well as for the geographic regions of key pre-filled syringe types (value and volume). The advantages that will drive the growth of pre-filled syringes include ease of administration, improved safety, reduced risk of contamination, elimination of medication errors, low incidence of needlestick injuries, accurate dosing and reduction in medical expenditure due to reduced visits to healthcare facilities. When compared to standard injectables, the pre-filled syringes market is still evolving, and its use is slowly increasing. Developed countries have shown a strong adoption rate for pre-filled syringes whereas developing & ROW countries have often been slow in adopting this technology. During the forecast period, however, the adoption rate will witness a healthy growth in emerging markets, and will witness a growth rate above that of developed geographies such as the US and in Europe. The market is highly consolidated and is currently dominated by key global players such as Abbott Labs, Becton Dickinson, Baxter, Nipro Corporation, Schott, Gerresheimer, West Pharmaceutical, Ypsomed, Bespak and Unilife Corporation. Other companies such as Haselmeier; Weigao Group, Nuova Ompi (Stevanato Group), Owen Mumford and Vetter Pharma are likely to foster innovation in the coming years. The Global Pre-filled Syringe Market 2014-2024 report includes over 125 tables, charts and graphs quantifying and forecasting the market in detail. In addition, the report offers 14 profiles of the leading PFS companies in the market alongside 3 expert interviewees offering key insights into the state of the market currently and in the future;
Table of Contents 1- Executive Summary 1.1 Global Pre-filled Syringes Market Review 1.2 Chapter Breakdown 1.3 Research and Analysis Methods 1.4 Drivers & Restraints of the Global Pre-Filled Syringe Market 2014-2024 1.4.1 Drivers 126.96.36.199 Growth of the Injectable Drugs Market 188.8.131.52 Success & Growth of Biologics 184.108.40.206 Increased Global Vaccination 220.127.116.11 Increased Drug Self-Administration 18.104.22.168 Technological Advances in the Manufacture of PFS 22.214.171.124 Advances in PFS Technology 1.4.2 Restraints 126.96.36.199 Increased Manufacturing / Distribution Costs 188.8.131.52 Alternative Drug Delivery Methods 184.108.40.206 Controlled Release 2 -Introduction to the Pre Filled Syringe Market 2.1 Introduction to Pre-filled Syringes 2.1.1 What are Pre-Filled Syringes 2.1.2 Market Overview of Pre-filled Syringes 2.1.3 An Increasingly Accessable Sector 2.1.4 Key Advances in the PFS Industry 2.2 Components of Pre-filled Syringes 2.3 Types of Pre-filled Syringes 2.3.1 Glass Syringes 2.3.2 Plastic Syringes 2.4 Classification of Pre-filled Syringes 2.4.1 Single-chamber and Dual-Chamber 2.4.2 Type of needle 2.5 Injection delivery devices 2.5.1 Pen Injectors 2.5.2 Insulin pens 2.5.3 Auto-Injectors 2.5.4 Needle-Free Injectors 2.5.5 Drugs available in Pre-filled Syringes 2.6 Concerns over needle stick Injuries 3 -Global Pre-Filled Syringe; Market Revenue and Volume Forecasts to 2024 3.1 Global Market Overview 3.1.1 Global Pre-filled Syringes Market Revenue, 2013-2024 3.1.2 Global Pre-filled Syringes Market Volume, 2013-2024 3.2 Glass Pre-filled syringes 3.2.1 Global Glass Pre-filled Syringes Market Revenue, 2013-2024 3.2.2 Global glass Pre-filled Syringes Market size, 2013 – 2024 3.3 Plastic Pre-filled syringes 3.3.1 Global Plastic Pre-filled Syringes Market Revenue, 2013 – 2024 3.3.2 Global Plastic Pre-filled Syringes Market size, 2013 – 2024 4 – Key Geographies in the Global Pre-Filled Syringe Market 2014-2024 4.1 Global Market Overview 4.2 The North America PFS Market 2013-2024 4.2.1 Key drivers in the North American PFS market 220.127.116.11 Increase in Cancer Treatment 18.104.22.168 Spending on multiple sclerosis (MS) 22.214.171.124 Increase in Diabetes Prevalence 126.96.36.199 Healthcare Expenditure 188.8.131.52 Spend on Vaccination 184.108.40.206 Regulatory Environment for Pre-Filled Syringes 4.3 The Europe PFS Market 2013-2024 4.3.1 Key factors that will drive the PFS market in Europe 220.127.116.11 Favourable reimbursement policies 18.104.22.168 Increased Spend on Healthcare 22.214.171.124 Increase in Europe Wide Diabetic Population 126.96.36.199 Strong contribution to the Biosimilar Market 188.8.131.52 Increase in Cancer Treatment 184.108.40.206 Regulatory Environment 4.4 The Asia Pacific PFS Market 2013-2024 4.4.1 Key drivers of the APAC PFS Market 220.127.116.11 Emerging Middle Classes 18.104.22.168 APAC Diabetes Market 22.214.171.124.1 China Diabetic Market 126.96.36.199.2 India Diabetic Market 188.8.131.52.3 Japanese Diabetic Market 184.108.40.206 Increase in Vaccination demand 220.127.116.11.1 Japanese Vaccination Market 18.104.22.168.2 India Vaccination Market 22.214.171.124.3 China Vaccination Market 126.96.36.199 Growing Cancer Drugs Market Across APAC 188.8.131.52.1 Japanese Cancer Drugs Market 184.108.40.206 Increased Biotechnology Across APAC 220.127.116.11.1 China Biotechnology 18.104.22.168.2 India Biotechnology 22.214.171.124.3 Japan Biotechnology 4.5 The Rest of the World PFS Market 2013-2024 4.5.1 Key drivers of the ROW PFS market 126.96.36.199 Increased demand for Vaccination 188.8.131.52.1 Russian demand for Vaccination 184.108.40.206.2 Brazil Vaccination Landscape 220.127.116.11 Increasing prevalence of Diabetes 18.104.22.168.1 The Brazilian Diabetes Sector 22.214.171.124.2 The Russia Diabetes Sector 126.96.36.199 Increased Healthcare Spending 5 -Leading Therapeutic Segments for Pre-Filled Syringes 2013-2024 5.1 Biologics 5.1.1 Next Generation Biologics 5.1.2 Biologics Pipeline 5.1.3 Key Biologics Exiting Patent 5.2 Biosimilars 5.2.1 Monoclonal Antibodies 5.2.2 Insulin 5.2.3 Erythropoietin 5.2.4 Interferons 5.2.5 G-CSF 5.2.6 Human Growth Hormones 5.3 Vaccines 5.4 Antirheumatics 5.5 Anticoagulants 5.6 Diabetes 5.7 Multiple Sclerosis (MS) 6 - SWOT Analysis of the Global Pre-Filled Syringes Market 2014-2024 6.1 Strengths 6.1.1 Ease of use 6.1.2 Accurate Dosage 6.1.3 Reduced Incidence of Needlestick Injuries 6.1.4 Economic advantages 6.2 Weaknesses 6.2.1 Product stability/compatibility issue 6.2.2 Air bubbles during filling 6.2.3 Device Operation issues 6.2.4 Extractables and Leachables contamination 6.3 Opportunities 6.3.1 Increase in the number of self-injecting patients 6.3.2 Growth of Biologics & Biosimilars 6.3.3 Geographic expansion 6.3.4 Vaccination Programmes 6.3.5 Ageing population 6.4 Threats 6.4.1 Alternative Drug Delivery Platforms 6.4.2 Manufacturing complexities 6.4.3 Manufacturer Recalls 6.4.4 Stringent Regulatory Environment 7 -Company Profiles 7.1. Abbott Labs 7.2: Baxter International 7.3: Becton Dickinson 7.4: Schott AG 7.5. Nipro Corporation 7.6: Gerresheimer AG 7.7. West Pharmaceutical Services 7.8. Ypsomed Holding AG 7.9: Bespak 7.10: Unilife Corporation 7.11: Haselmeier 7.13: Weigao Group 7.14: Owen Mumford 8 -Expert Opinion 8.1 Schott Kaisa 8.2 West Pharmaceuticals 8.3 Fresenius Kabi
List of Tables Table 1.4: Drivers & Restraints of the Global Pre-Filled Syringe Market 2014-2024 Table 188.8.131.52: Total Diabetics & Treatment Statistics US, 2013 (million people) Table 2.2.1: Components of PFS Table 2.2.2: Key components and description of PFS Table 184.108.40.206: Advantages of dual-chamber system Table 2.5.1: Classification of injectors depending upon of the type Use and User Table 220.127.116.11: Different brands of Insulin available in the market Table 18.104.22.168: Benefits of Auto-injector Table 22.214.171.124: Advantages of needle-free Table 126.96.36.199: Categories of drugs where PFS are used: Table 188.8.131.52: Breakdown of Pre-filled Syringes market by region, 2013 ($ bn) Table 184.108.40.206: Pre-filled Syringe Market; Total Revenue, Total Units, Glass Revenue & Plastic Revenue 2013-2024 ($/bn, %) Table 220.127.116.11: Total Revenue, Total Units, Glass & Plastic 2013, 2014, 2019 & 2024 ($/bn, %) Table 4.1.1: Global PFS Market Revenue Forecast 2013-2024 ($/bn, %) Table 4.1.2: Forecast of Regional CAGR 2014-2024 (%) Table 4.1.3; Regional PFS Market Share Breakdown (%) Table 4.1.4: Forecast of Regional Market Share 2014, 2019 & 2024 ($/bn & %) Table 4.1.5: Forecast of Global PFS Revenue & Total Units Shipped 2013-2024 ($/bn & billion units) Table 4.1.6: Regional PFS Unit Sales (billion) Table 4.2.1: The North America PFS Market Forecast 2013-2024 ($/bn & AGR %) Table 4.2.2: The North America PFS Unit Forecast 2013-2024 (billion) Table 4.2.3: Estimated Incidence, Mortality, and Prevalence of Cancer Worldwide and US - 2012 Table 4.2.4: Total Diabetics & Treatment Statistics, US, 2013 (million people) 4.2.5: Diabetes population, prevalence and healthcare expenditure in the US and Canada (2013) Table 4.2.6: US Healthcare Spending Per Capita 2000-2013 ($, %) Table 4.3.1: The Europe PFS Market 2013-2024 ($/bn) Table 4.3.2: Forecast of European PFS Unit Sales 2013-2024 (Billion Units) Table 4.3.3 PFS Revenue, by Geography, Europe 2013 ($/ bn / %) Table 4.3.4: EU5 GDP & Healthcare Spending, 2012 ($/bn) Table 4.3.5: Diabetes population, prevalence and healthcare expenditure in Europe – 2013 ($) Table 4.3.6: Estimated Incidence and Mortality rate of Cancer in Europe - 2013 Table 4.4.1: Asia-Pacific & Global PFS Market ($/bn & AGR) Table 4.4.2: Forecast of Asia-Pacific PFS Unit Sales 2013-2024 (Billion Units) Table 4.4.3: GDP Growth, India & China 1990-2010 ($/bn, %) Table 4.4.4: Number of Population with Diabetes in China 2008-2030 Table 4.4.5: China Diabetes Annual Figures, 2013 Table 4.4.6: India Diabetes Annual Figures, 2013 Table 4.4.7: Japan Diabetes Annual Figures, 2013 Table 4.4.8: Incidence, Mortality, and Prevalence of Cancer Worldwide, China, India & Japan 2012 Table 4.4.9: China Pharmaceutical Market for Oncology, 2008 – 2013 Table 4.4.10: APAC Biologics & Biosimilars Market Size 2013 ($/bn) Table 4.4.11: Key Biosimilars Approved in India 2014 Table 4.4.12: PMDA Approved Biosimilars in Japan 2014 Table 4.5.1: The Rest of the World PFS Market 2013-2024 ($/bn, %) Table 4.5.2: Forecast of ROW PFS Unit Sales 2013-2024 (Billion Units) Table 4.5.3; Russian Vaccines Profile 2014 Table 4.5.4: Brazilian Vaccines Profile 2014 Table 4.5.5: Diabetes population, prevalence and healthcare expenditure in Brazil, 2013 Table 4.5.6: Diabetes population, prevalence and healthcare expenditure in Russian, 2013 Table 4.5.7: GDP Growth Brazil & Russia 2000-2010 ($/bn) Table 4.5.8: Russia & Brazil GDP & Healthcare Spend 2000, 2005 & 2010 ($/bn) Table 5.1.1: Global Biologics Market Size by Region, 2013 ($/bn) Table 5.1.2: Biologic medicines under development-by therapeutic category 2014 Table 5.1.3: Biologic medicines under development-by product category 2014 Table 5.1.4: Expiry dates for major patents on best-selling biological products 2011-2024 Table 5.1.5: Key products potential targeted by biosimilar developers post patent expirations Table 5.2.1: Global Biosimilars Market Size by Region, 2013 ($/bn) Table 5.2.2: Key Drivers of the Global Biosimilar Market Table 5.2.3: Key Restraints in the Global Biosimilar Market 2014 Table 5.2.4: Biologics, which lose patent and the opportunity for Biosimilars 2013 ($/bn) Table 5.2.5: Biologics under different phases of trials Table 5.3.1: Vaccine manufacturers’ classification for supply Table 5.3.2: Top 10 best-selling vaccine, manufacturer and application 2013 Table 5.5.3: Global Anticoagulants market by region, 2013 ($/bn, %) Table 5.6.1: Top 10 selling diabetes drugs, 2013 Table 6.1: SWOT Analysis of the Global Pre-filled Syringes Market 2014-2024 Table 6.3.1: Diabetes in the US, Diagnosed, Undiagnosed and New Cases 2012 Table 6.3.2: BRIC Population, Healthcare Expenditure per Capita 2006 / 2012 ($/p/a) Table 7.1.1: Abbott Labs Key PFS/BGMS Products, 2014 Table 7.2.1: Baxter International Key PFS Products, 2014 Table 7.3.1: Key Becton Dickinson PFS / IV Products, 2014 Table 7.4.1: Schott Key PFS/Needle Products, 2014 Table 7.5.1: Nipro Corporation Key PFS / Related Products, 2014 Table 7.6.1: Gerresheimer Key PFS / Syringe Products, 2014 Table 7.7.1: West Pharmaceutical Key Products, 2014 Table 7.8.1: Ypsomed Key PFS/Injection Products, 2014 Table 7.9.1: Bespak Key PFS / Syringe Products, 2014 Table 8.10.1: Unilife Corporation Key PFS/Injection Products, 2014 Table 7.11.1: Haselmeier Key PFS / Injection Products 2014 Table 7.13.1: Weigao Group Key PFS / Syringe Products, 2014 Table 7.14.1: Owen Mumford Key PFS / Syringe Products, 2014 List of Figures Figure 2.6.1: Breakdown of Risk of Needlestick Injury 2014 Figure 18.104.22.168: Forecast of the Global Pre-filled Syringes Market, 2013-2024 ($/bn) Figure 22.214.171.124: Breakdown of Pre-filled Syringes market by region, 2013 ($/bn) Figure 126.96.36.199: Forecast of the Global Pre-filled Syringes Market, 2013-2024 (bn units) Figure 188.8.131.52: Forecast of the Global Glass Pre-filled Syringes Market, 2013-2024 ($/bn) Figure 184.108.40.206: Forecast of the Global Glass Pre-filled Syringes Market, 2013-2024 (bn units) Figure 220.127.116.11: Forecast of the Global Plastic Pre-filled Syringes Market, 2013-2024 ($/bn) Figure 18.104.22.168: Forecast of the Global Plastic Pre-filled Syringes Market, 2013-2024 (bn units) Figure 4.1.1: Global PFS Market Revenue Forecast 2013-2024 ($/bn, %) Figure 4.1.2 Percentage Share of the Global PFS Market, 2014 (%) Figure 4.1.3 Percentage Share of the Global PFS Market, 2019 (%) Figure 4.1.4 Percentage Share of the Global PFS Market, 2024 (%) Figure 4.2.1 PFS Unit sales, US, (billions) 2013-2024 Figure 4.2.2 US Healthcare Spending Per Capita 2000-2013 ($) Figure 4.3.1 PFS Unit sales, Europe, (billions) 2013-2024 Figure 4.3.2 PFS Market Revenue, by Geography, Europe, 2013 (%) Figure 4.3.3: EU5 GDP & Healthcare Spending, 2012 ($/bn) Figure 4.3.4 China Per Capita Disposable Income 2005-2013 ($) Figure 4.4.1 PFS Unit sales, ROW, (billions) 2013-2024 Figure 4.4.2 Russia & Brazil Healthcare Spend 2000, 2005 & 2010 ($/bn) Figure 5.1.1: Global Biologics Market Forecast, 2013-2024 ($/bn) Figure 5.1.2: Global Biologics Market Size by Region, 2013 ($/bn) Figure 5.2.1: Global Biosimilar Market Forecast, 2013-2024 ($/bn) Figure 5.2.2: Global Biosimilar Market Size by Region, 2013 ($/bn) Figure 5.3.1: Global Vaccine Market Forecast, 2013-2024 ($/bn) Figure 5.4.1: Global Anti-rheumatics Market Forecast, 2013-2024 ($/bn) Figure 5.4.2: Market Share of Key Players in Anti-rheumatics Market, 2013 (%) Figure 5.4.3: Market Share of Key Brands in Anti-rheumatics Market, 2013 (%) Figure 5.5.1: Global Anticoagulants Market Forecast, 2013-2024 ($/bn) Figure 5.5.2: Global Anticoagulants Market, by region, 2013 (%) Figure 5.6.1: Global Anti-diabetic Drugs Market Forecast, 2013-2024 ($/bn) Figure 5.7.1: Breakdown of Multiple Sclerosis Market, by Region; 2013, ($/bn) Figure 5.7.2: Forecast of the Global Multiple Sclerosis Market, 2013-2024 ($/bn) Figure 5.7.3: Top 5 MS Brands, Market Share, 2013 Figure 8.1.1: Abbotts Regional Sales Breakdown, 2013 Figure 8.2.1: Baxter Regional Revenue Breakdown 2013 Figure 8.4.1: Schott’s Net Sales, by Region, 2013 Figure 8.5.1: Nipro Regional Net Sale Breakdown, 2013-2014 Figure 8.6.1: Gerresheimer AG Regional Net Sales, 2013-14 Figure 8.7.1: West Pharmaceutical Regional Net Sales, 2013-14
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.